Table 1. Patient characteristics and metrics per TTR quartile.
| Values | Period (months) | |||||
|---|---|---|---|---|---|---|
| 4 – 24 | 6 – 24 (Sensitivity analysis) | |||||
| Q1 N = 303 | Q2 N = 306 | Q3 N = 305 | Q4 N = 306 | Total N = 1220 | N = 934 | |
| Demographics | ||||||
| Age (mean/±SD) | 62.02 (±15.92) | 64.58 (±13.83) | 64.49 (±14.48) | 64.30 (±14.63) | 63.85 (±14.75) | 64.75 (±14.03) |
| Female (%) | 50.8 | 55.2 | 52.5 | 44.1 | 50.7 | 51.5 |
| Anticoagulation | ||||||
| INR (mean/±SD) | 2.56 (± 1.25) | 2.67 (± 1.10) | 2.61 (± 0,89) | 2.54 (± 0,62) | 2.60 (±0.88) | 2.60 (±0.96) |
| INR (median/IQR) | 2.22 (1.70-3.16) | 2.50 (1.97-3.20) | 2.48 (2.06-2.98) | 2.44 (2.13-2,78) | 2.44 (1.99-3.00) | 2.43 (2.00-3.00) |
| TTR (mean/±SD) | 32.6% (±11.5%) | 51.2% (±3.3%) | 62.0% (±3.2%) | 80.2% (±9.8%) | 56.6% (±18.9%) | 58.0% (±16.2%) |
| TTR (median/IQR) | 36% (28-42%) | 52% (48-54%) | 62% (59-65%) | 78% (72-86%) | 58% (47-68%) | 57.0% (45-68%) |
| INR tests per patient (mean/±SD) | 12.79 (±8.09) | 17.49 (±9.65) | 18.00 (±9.27) | 14.20 (±8.40) | 15.63 (±9.13) | 18.44 (±8.60) |
| Risk factors and baseline conditions | ||||||
| CHA2DS2-VASc (mean/±SD) | 2.38 (±1.72) | 2.46 (±1.69) | 2.55 (±1.69) | 2.44 (±1.74) | 2.45 (±1.71) | 2.58 (±1.72) |
| Stroke (%) | 13.9 | 12.1 | 11.5 | 17.3 | 13.7 | 14.6 |
| Hypertension (%) | 33.3 | 39.2 | 43.6 | 37.9 | 38.5 | 41.3 |
| Diabetes (%) | 13.2 | 14.4 | 15.4 | 11.4 | 13.6 | 14.5 |
| Chronic kidney failure (%) | 4.6 | 2.0 | 4.3 | 2.6 | 3.4 | 3.0 |
| Congestive heart failure (%) | 20.5 | 18.3 | 21.3 | 19.0 | 19.8 | 21.1 |
| Region | ||||||
| Southeast | 86.8 | 85.9 | 85.6 | 84.3 | 85.7 | 85.9 |
| Central | 6.9 | 8.2 | 8.5 | 9.8 | 8.4 | 8.6 |
| South and Northeast | 6.3 | 6.0 | 5.9 | 5.9 | 6.0 | 5.5 |
| Concomitant medications | ||||||
| Phenprocoumon | 11 | 6 | 5 | 11 | 33 | 26 |
| Aspirin | 10 | 6 | 15 | 0 | 31 | 25 |
| Clopidogrel | 7 | 5 | 2 | 2 | 16 | 9 |
| Aspirin + clopidogrel | 3 | 0 | 1 | 0 | 4 | 2 |
| Statins | 27 | 29 | 33 | 29 | 118 | 99 |
| Nitrate | 2 | 3 | 5 | 6 | 16 | 14 |
| Amiodarone | 1 | 3 | 3 | 3 | 10 | 7 |
| Follow-up | ||||||
| Months of monitoring (mean/±SD) | 13.87 (± 7.37) | 16.04 (± 7.29) | 18.02 (± 7.02) | 17.24 (± 7.11) | 16.30 (± 7.36) | 18.13 (± 6.45) |
| Months of monitoring (median/IQR) | 14.00 (7.0-20.0) | 17.00 (9.0-23.0) | 21.00 (12.0-24.0) | 19.00 (11.0-23.0) | 18.00 (10.0-23.0) | 20.00 (13.0-23.0) |
CHA2DS2-VASc: congestive heart failure, hypertension, age, diabetes mellitus, stroke/TIA, vascular disease, age, sex category; IQR: interquartile range; SD: standard deviation; TTR: time in therapeutic range.